Pin10 Cost Effectiveness Oftipranavir in Treatment-Experienced Hiv Patients in the Usa

Simpson, KN; Chumney, Ecg; Cb, Hicks; Finnern, Henrik W.

doi:10.1016/s1098-3015(10)64786-9

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct comparisons between the results of this analysis and those of economic studies of other PI options for treatment-experienced patients are difficult. Simpson and colleagues [58] have published a US cost-effectiveness estimate of US$56 315 per QALY gained for TPV/r when compared with currently available PIs (excluding DRV/r). [58] This estimate was based on the results of the RESIST 1 and 2 trials, however, which enrolled a patient population with more advanced disease characteristics and treatment experience, more comparable to the highly treatment-experienced patients enrolled in the POWER trials than to the patients modelled in our analysis.…”

Section: Discussionmentioning

confidence: 99%

“…Simpson and colleagues [58] have published a US cost-effectiveness estimate of US$56 315 per QALY gained for TPV/r when compared with currently available PIs (excluding DRV/r). [58] This estimate was based on the results of the RESIST 1 and 2 trials, however, which enrolled a patient population with more advanced disease characteristics and treatment experience, more comparable to the highly treatment-experienced patients enrolled in the POWER trials than to the patients modelled in our analysis. [32,45,59] Simpson et al [60] also recently published a costeffectiveness study of HAART regimens including LPV/r compared with ritonavir-boosted atazanavir in treatment-experienced patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial

et al. 2010

View full text Add to dashboard Cite

From a US societal perspective and based on an analysis of the patients with primary IAS-USA PI RAMs enrolled in the darunavir phase III TITAN trial, a highly active antiretroviral therapy (HAART) regimen containing DRV/r 600/100 mg bid is estimated to be a cost-effective therapy when compared with a HAART regimen containing LPV/r, for the management of treatment-experienced, PI-resistant, HIV-infected adults with a broad range of previous PI use/failure.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial

et al. 2010

View full text Add to dashboard Cite

show abstract

Tipranavir

Orman

Perry

2008

Drugs

View full text Add to dashboard Cite

Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its bioavailability. The durable efficacy of tipranavir, in combination with low-dose ritonavir (tipranavir/ritonavir 500 mg/200 mg twice daily), has been demonstrated in well designed trials in treatment-experienced adults infected with multidrug-resistant strains of HIV-1. In treatment-experienced adults with HIV-1 infection receiving an optimized background regimen, viral suppression was greater and immunological responses were better with regimens containing tipranavir/ritonavir than with comparator ritonavir-boosted PI-containing regimens. The efficacy benefit appeared to be more marked in patients receiving two fully active drugs in the regimen, with the combination of tipranavir/ritonavir and enfuvirtide (for the first time) appearing to be the most successful. Although tipranavir is generally well tolerated, clinical hepatitis and hepatic decompensation, and intracranial haemorrhage have been associated with the drug. Tipranavir also has a complex drug-interaction profile. Thus, tipranavir, administered with ritonavir, is an effective treatment option for use in the combination therapy of adults with HIV-1 infection who have been previously treated with other antiretroviral drugs.

show abstract

Tipranavir cost effective in treatment-experienced HIV

2006

Pharmacoecon. Outcomes News

View full text Add to dashboard Cite

Pin10 Cost Effectiveness Oftipranavir in Treatment-Experienced Hiv Patients in the Usa

Cited by 3 publications

References 0 publications

US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial

US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial

Tipranavir

Tipranavir cost effective in treatment-experienced HIV

Contact Info

Product

Resources

About